A comparative study of the effects of risperidone and olanzapine on metabolic parameters of schizophrenic patients


  • Sanjay B. Nanotkar Department of Medicine, MGIMS, Sevagram, Wardha, Maharashtra,India
  • Balwant K. Choure Department of Pharmacology, RCSM Govt. Medical College Kolhapur, Maharashtra,India
  • Devesh D. Gosavi Department of Pharmacology, MGIMS, Sevagram, Wardha, Maharashtra,India




Risperidone, Olanzapine, Metabolic, Parameters, BMI, Metabolic syndrome


Background: Risperidone and olanzapine are the most commonly prescribed antipsychotic drugs. There is an overwhelming need to look into the adverse effects induced by these drugs; metabolic disturbance being one of the important of them. Metabolic disturbance induced by these drugs is a little searched domain; Most of the literature on their metabolic adverse effects is based on retrospective analysis. Moreover there is a distinct lack of information on the metabolic adverse effects of these drugs in Indian subjects with special reference to rural population.

Methods: The present study was a prospective, open label, observational study conducted on 189 consecutive new subjects who were prescribed either risperidone (n=93) and olanzapine (n=96) in the psychiatry department of a rural medical college and hospital.

Results: Patients on treatment of risperidone (n=84) showed an increase in all the variables except for HDL cholesterol levels which showed fall. The increases in weight, body mass index were found to be extremely significant (p<0.001). While the rise in the systolic and diastolic blood pressure, fasting sugars and triglycerides, changes was not significant. The fall in HDL cholesterol was not statistically significant.

Conclusions: We conclude from this study that both risperidone and olanzapine have propensity to produce metabolic syndrome in subjects who use them. When compared, olanzapine has a higher chance to produce metabolic syndrome in subjects who were prescribed it, as compared to subjects who were on risperidone.


Bhanji NH, Tempier R, Bhanji NH TR. Managing schizophrenia during the stable phase: Is there consensus among practice guidelines? Can J psychiatry. 2002;47(1):47.

Wahlbeck K, Tuunainen A, Ahokas ALS. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology. 2001;155:230-3.

Glick IBP. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. International clinical psychopharmacology. 2002;17:65-8.

Davis JM, Chen NGI, Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-64.

Conley RR. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765-74.

Marder SR, Davis JM CG, Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-46.

Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-65.

Aronson JK. Risk perception in drug therapy. 2006;135-7.

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.

Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44(8):778-83.

Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425-33.

Cooper C, Bebbington P, King M, Brugha T, Meltzer H, Bhugra D, et al. Why people do not take their psychotropic drugs as prescribed: results of the 2000 national psychiatric morbidity survey. Acta Psychiatr Scand. 2007;116(1):47-53.

Lingeswaran A, Harshashetty, Kigshuklohan, Amitparamel SG. A letter to the editor. Ind J Ppharmacol. 2010;42.

Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry. 2001;62(2):5-12.

Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1-17.

Ingole S, Belorkar NR, Waradkar P, Shrivastava M. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients. Indian J Physiol Pharmacol. 2009;53(1):47-54.

Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(1):1-93.

Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry. 2004;65(5):686-9.

Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27-35.

Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry. 2006;51(8):502-11.

Garyfallos G, Dimelis D, Kouniakis P, Sidiropoulos N, Karastergiou A, Lavrentiadis G, et al. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. Eur Psychiatry. 2003;18(6):320-1.

Ganguli R, Brar JS, Ayrton Z. Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophr Res. 2001;49(3):261-7.

Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry. 2004;65(4):547-50.

Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60(11):767-70.

Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry. 1999;156(9):1471-2.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007;164(3):415-27.

Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT, et al. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry. 2001;34(6):223-31.

Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry. 2011;53(2):128-33.

Kinon BJ, Liu-Seifert H, Ahl J, Ahmed S, Baker RW. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study. Ann N Y Acad Sci. 2004;1032:295-6.

Krane-Gartiser K, Breum L, Glumrr C, Linneberg A, Madsen M, Koster A, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry. 2011;65(5):345-52.

Cerit C, Vural M, Bos Gelmez SU, Ozten E, Aker AT, Yildiz M. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Psychopharmacol Bull. 2010;43(4):22-36.




How to Cite

Nanotkar, S. B., Choure, B. K., & Gosavi, D. D. (2016). A comparative study of the effects of risperidone and olanzapine on metabolic parameters of schizophrenic patients. International Journal of Basic & Clinical Pharmacology, 5(3), 814–819. https://doi.org/10.18203/2319-2003.ijbcp20161526



Original Research Articles